by Eli Lilly
Eligible for BMI of 27* or 30 kg/m²*Check Eligibility
*Appointments after 1st of September will incur a different charge. We will update the prices again on 1st of September
Mounjaro (tirzepatide) is an innovative injectable prescription medication for chronic weight management in adults. It combines the effects of GIP and GLP-1 hormones to regulate appetite and improve metabolic function.
As the first dual GIP and GLP-1 receptor agonist, Mounjaro offers superior weight loss results compared to single-action medications. It targets multiple pathways involved in weight regulation for comprehensive effects.
Clinical trials show Mounjaro can help patients lose up to 22% of their body weight when combined with lifestyle changes. The medication follows a structured dose escalation to optimize tolerability.
Mounjaro is approved for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions like type 2 diabetes.
Mounjaro treatment typically begins with a 4-week dose escalation period at 2.5mg before increasing in 2.5mg increments every 4 weeks until reaching the target maintenance dose (ranging from 5mg to 15mg weekly based on individual response). This gradual titration helps minimize gastrointestinal side effects.
Mounjaro is a prescription-only medication. You'll need to complete a consultation with one of our healthcare professionals to determine if it's suitable for you.
WeightGone